MedAvail Holdings (MedAvail Holdings) ROCE % : -75.98% (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is MedAvail Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. MedAvail Holdings's annualized ROCE % for the quarter that ended in Jun. 2023 was -75.98%.

MedAvail Holdings ROCE % Historical Data

The historical data trend for MedAvail Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedAvail Holdings ROCE % Chart

MedAvail Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

ROCE %

-201.38

-70.98

-93.60

-160.54

MedAvail Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
ROCE %	Get a 7-Day Free Trial										-65.32	-105.45	-122.80	-171.56	-75.98

MedAvail Holdings ROCE % Calculation

MedAvail Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-46.42	/	( ( (38.143 - 7.505)	+	(33.132 - 5.941) )	/ 2 )
	=	-46.42	/	( (30.638	+	27.191)	/ 2 )
	=	-46.42	/	28.9145
	=	-160.54 %

MedAvail Holdings's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	-21.4	/	( ( (35.714 - 5.134)	+	(29.908 - 4.156) )	/ 2 )
	=	-21.4	/	( ( 30.58	+	25.752 )	/ 2 )
	=	-21.4	/	28.166
	=	-75.98 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

MedAvail Holdings (OTCPK:MDVLQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

MedAvail Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of MedAvail Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

MedAvail Holdings (MedAvail Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » MedAvail Holdings Inc (OTCPK:MDVLQ) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4720 East Cotton Gin Loop, Suite 220, Phoenix, AZ, USA, 85040

Website

https://www.medavail.com

MedAvail Holdings Inc is a telehealth-enabled pharmacy technology company. It operates in two segments: Retail Pharmacy Services and Pharmacy Technology. It generates the majority of revenue from the Retail Pharmacy Services segment, which is into operating SpotRx, a full-service retail pharmacy utilizing MedAvail's automated pharmacy technology, primarily servicing Medicare patients in the United States. The Pharmacy Technology segment develops and commercializes the MedCenter for direct sale or lease to third-party customers.

Executives

Ramona Seabaugh	officer: Chief Financial Officer	C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4
Michael R Kramer	director	3910 BRICKWAY BLVD, SANTA ROSA CA 95403
Paul D Johnson	director	440 N BARRANCA AVE #3550, COVINA CA 91723
Glen D. Stettin	director	C/O EXPRESS SCRIPTS HOLDING COMPANY, ONE EXPRESS WAY, ST. LOUIS MO 63121
Mark Edward Doerr	director, officer: Chief Executive Officer	C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4
Abg Wtt-medavail Ltd	10 percent owner	15 QUEENS ROAD CENTRAL, UNIT 3002-3004, 30TH FLOOR, GLOUCESTER TWR, THE LANDMARK, HONG KONG F4 0000000000
Redco Ii Master Fund, L.p.	director, 10 percent owner	ONE LETTERMAN DRIVE, BLDG D, STE D3-300, SAN FRANCISCO CA 94129
Alyeska Fund Gp, Llc	10 percent owner	77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Investment Group, Llc	10 percent owner	77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Investments, Llc	10 percent owner	77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Anand Parekh	10 percent owner	77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Master Fund, L.p.	10 percent owner	77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Investment Group, L.p.	10 percent owner	77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Steven Hess	officer: Executive Vice President	C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4
Edwin Kilroy	director, officer: Chief Executive Officer	C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4